Bridging Health Equity Gaps: Creyos Launches an Even More Accessible Patient Experience
November 05, 2024 08:00 ET
|
Creyos
Toronto, Canada, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Creyos, a leader in cognitive and behavioral health assessment, has announced significant enhancements to its online platform to improve...
Green Bioactives Reports Remarkable Cognitive Benefits of its Newly Launched Memory-boosting Nutraceutical Product, GBL-Memory¹
May 30, 2024 03:00 ET
|
Green Bioactives Limited
A clinical study, published in the journal Food Science and Nutrition, showed that GBL-Memory1, a unique combination of L-theanine and Fructooligosaccharides, can improve memory by up to 10.1%...
Blue California completes groundbreaking human clinical trial on ErgoActive® ergothioneine intervention for cognitive function, memory, and sleep
February 05, 2024 04:00 ET
|
Blue California Ingredients
Rancho Santa Margarita, Calif., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Blue California, an industry leader in science-driven ingredient development, announced the successful completion of a...
Axsome Therapeutics Presents New Data from the EVOLVE Open-Label Trial Demonstrating Effects of AUVELITY® on Cognitive and Physical Functioning in Patients with Major Depressive Disorder at the American College of Neuropsychopharmacology (ACNP) 2022 Annual Meeting
December 07, 2022 07:00 ET
|
Axsome Therapeutics, Inc.
Improvement in cognitive and physical functioning, measured by the CPFQ patient-rated scale, starting at week 1 and sustained over 12 months Improvement in disability, measured by the SDS, starting...
Healthy Extracts Introduces Breakthrough Nutraceutical Formulation, Ultimate Brain Nutrients ACTIVATE™, Clinically Proven to Enhance Key Brain Activity by 46%
July 08, 2021 08:31 ET
|
Healthy Extracts Inc
LAS VEGAS, July 08, 2021 (GLOBE NEWSWIRE) -- Healthy Extracts Inc. (OTCQB: HYEX), a leading developer and manufacturer of science-forward, clinically proven, plant-based products for heart and brain...
Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in CONCERT Phase 2 Trial in Narcolepsy
December 03, 2019 06:00 ET
|
Axsome Therapeutics, Inc.
Demonstrated statistically significant reduction in cataplexy attacks compared to placebo (p<0.001 on primary endpoint) Reduced excessive daytime sleepiness compared to placebo (p=0.003 on ESS;...
Elemental Cognition Adds Three Notable Advisors
October 10, 2019 07:00 ET
|
Elemental Cognition
WILTON, Conn., Oct. 10, 2019 (GLOBE NEWSWIRE) -- Elemental Cognition, the artificial intelligence company founded and led by Dr. David Ferrucci, creator of IBM’s Watson, and funded to date by global...
Aptinyx Presents Data Demonstrating Positive Activity of NYX-458 on Cognitive Performance and Biomarkers in a Preclinical Model of Head Injury
August 21, 2019 08:33 ET
|
Aptinyx Inc.
EVANSTON, Ill., Aug. 21, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous...
Aptinyx Reports Second Quarter 2019 Financial Results and Highlights
August 12, 2019 06:33 ET
|
Aptinyx Inc.
Reported that NYX-2925 met primary and secondary endpoints in Phase 2 fibromyalgia study On track to initiate three additional Phase 2 studies in 2H 2019 across pipeline of CNS product candidates ...
Journal of Clinical Psychiatry Publishes Positive Results of Cognitive Performance From Phase 2B Trial of Roluperidone, Under Development by Minerva Neurosciences for the Treatment of Negative Symptoms in Schizophrenia
May 17, 2018 08:00 ET
|
Minerva Neurosciences, Inc
WALTHAM, Mass., May 17, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...